Distant spread disease is defined as a disease with either pathologically or radiologically confirmed spread to distant skin, visceral organs, or bone. Locoregional spread disease entails being either pathologically or radiologically confirmed as spread to any lymph node(s). Local or locally advanced disease was defined as a disease confined to the primary tumour location and close surroundings. Further studies are needed to improve outcomes for patients with MM.ĭue to the different staging classifications applied to different tumour locations (e.g., TNM and Extent of Disease), and concurrent changes of the TNM staging system over time, MM were reclassified as local or locally advanced disease, locoregional spread disease, or distant spread disease. However, the prognosis of MM patients is still lower compared to CM, and the median OS of patients treated with immune and targeted therapies remains fairly short. Conclusion: Since the introduction of immune and targeted therapies, OS has improved for patients with MM. Diagnosis in the period 2014–2019, MM located in the female genital tract, and treatment with immune or targeted therapy were independent predictors for better OS.
Age ≥ 70 years at diagnosis, higher stage at diagnosis, and respiratory tract location were independent predictors for worse OS. The incidence remained stable over time (EAPC 3.0%, p = 0.4). The majority presented with local or locally advanced disease (66%). Results: In total, 1496 patients were diagnosed with MM during 1990–2019, mostly in the female genital tract (43%) and the head and neck region (34%). Independent predictors for OS were assessed by applying multivariable Cox proportional hazards regression models.
OS was calculated using the Kaplan–Meier method. The age-standardized incidence rate and estimated annual percentage change (EAPC) were calculated over the total study period. Methods: We obtained information on patients diagnosed with MM during 1990–2019 from the Netherlands Cancer Registry. This study aimed to assess trends in the incidence and survival of MM in the Netherlands against the background of new effective treatments that became available for advanced melanoma.
Over the years, immune and targeted therapy have become available and have improved overall survival (OS) for patients with advanced cutaneous melanoma (CM). Background: Mucosal melanoma (MM) is a rare tumour with a poor prognosis.
0 kommentar(er)
